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Tumors can be broadly placed into two categories: those
that are T cell-inflamed and those that are not, with
T cell-inflamed tumors having specific chemokine and
type I interferon gene expression signatures as well as
CD8+ tumor-infiltrating T cells (TIL). The fact that
these T cell-inflamed tumors are not destroyed by the
CD8+ TIL argues that mechanisms in the tumor micro-
environment must render the CD8+ TIL dysfunctional.
In agreement with this argument, baseline infiltration of
CD8+ T cells appears to be necessary for tumor regres-
sion in response to neutralizing antibodies against
CTLA-4 and PD-L1, indicating that these immunothera-
pies work predominantly on T cells already infiltrating
the tumor microenvironment. We analyzed CD8+ TIL
in the mouse B16.SIY model of melanoma to identify
additional immunotherapy targets that might synergize
with blockade of CTLA-4 and the PD-1/PD-L1 pathway.
Using knowledge from in vitro T cell anergy gene
expression profiling and phenotypic analysis, we found
that dysfunctional CD8+ TIL unexpectedly express sev-
eral co-stimulatory molecules, including 4-1BB. We
therefore investigated whether delivering positive signals
through co-stimulatory receptors, in combination with
blockade of specific inhibitory receptors, could act on
dysfunctional TIL to restore their function and induce
tumor regression. We found that an agonist anti 4-1BB
antibody synergized with inhibitory antibodies against
either CTLA-4 or PD-L1 to induce tumor regression of
established B16.SIY tumors. By using the S1P1 inhibitor
FTY720 to block T cell egress from lymph nodes, we
found that these combinations did not require newly
primed cells from the periphery for tumor regression,
arguing that they work directly in the tumor microenvir-
onment. Deeper analysis of TIL revealed expansion of
SIY-reactive CD8+ TIL and restored IL-2 production, as
well as decreased expression of inhibitory receptors
PD-1, LAG-3 and 2B4. Investigation of the mechanism
of increased TIL number revealed that proliferation of
the TIL was not enhanced with these combinations.
Rather, a marked decrease in apoptosis of SIY-reactive
TIL was observed, as measured by decreased active cas-
pase-3 levels during tumor regression induced by 4-1BB
combination immunotherapy. 4-1BB may therefore pro-
vide critical survival signals that rescue dying dysfunc-
tional CD8+ cells in the tumor microenvironment,
allowing them to be re-functionalized by CTLA-4 or
PD-L1 blockade to mediate tumor regression.
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